Pulmonary hypertension (PH) is a pathophysiological condition characterized by elevated pulmonary arterial pressure. It's a progressive disease with a high morbidity and mortality rate, making comprehensive understanding crucial for optimal patient management.
PH can be idiopathic, heritable, or associated with various conditions such as connective tissue diseases, congenital heart disease, portal hypertension, and HIV infection. The World Health Organization (WHO) classifies PH into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy.
PH often presents non-specifically, with symptoms such as dyspnea, fatigue, and chest discomfort. As the disease progresses, signs of right heart failure may become evident. A high index of suspicion is required for early diagnosis.
The diagnosis of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. Other tests, such as pulmonary function tests, a six-minute walk test, and cardiac MRI, can provide additional information about the severity and prognosis of the disease.
Treatment strategies for PH are complex and largely depend on the underlying cause. General measures include supplemental oxygen, diuretics, and anticoagulation. Specific therapies include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
Prognosis varies widely depending on the cause and severity of PH. Despite advances in treatment, PH remains a serious condition with a significant impact on quality of life and survival.
Understanding the fundamentals of PH is essential for healthcare professionals. Early recognition, comprehensive evaluation, and individualized treatment can significantly improve patient outcomes. Continuous research is needed to expand our knowledge and develop more effective therapies for this challenging disease.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation